Business1 hour ago
Naughty 😇•10%
Boldfit Seeks $80-100M Funding to Expand in India’s Fitness Market
Boldfit aims to raise $80-100 million from private equity to enhance its presence in India's booming fitness market. With a valuation of ₹3,000-4,000 crore, this D2C brand is poised for significant growth. The investment will help Boldfit capitalize on the increasing demand for fitness solutions in India, making it a key player in the industry.
⚖️ AI Verdict
"Boldfit is flexing its financial muscles to pump up growth!"
📢 Share Intel:
File ID: #333164Original Source: LiveMint Companies ↗
🤖 SINS Investigator
Ask about this Intel File
🕵️♂️
File Opened for Analysis
Ask me anything about the event, its implications, or who is responsible for the SINS!
Deepen Investigation
Related Intelligence Files
Business1 hour ago
SGB 2018-19 Series VI Redemption: Investors Gain 361% Today
SGB 2018-19 Series VI premature redemption starts today, offering investors a 361% return as RBI sets the price at ₹15,102 per unit. Those who purchased bonds at ₹3,276 will benefit significantly, excluding the 2.5% annual interest. This lucrative opportunity highlights the strong performance of sovereign gold bonds in the market.
View File→
Business1 hour ago
India's Family Businesses Surpass Saudi GDP; Ambani Richest
India's family businesses are now valued at $1.46 trillion, exceeding Saudi Arabia's GDP. Mukesh Ambani's family continues to lead as the richest in India. This remarkable growth highlights the economic power of family-run enterprises in India, showcasing their influence on both local and global markets.
View File→
Business1 hour ago
Unconditional Cash Transfers for Women in India: Impact on Welfare
Unconditional cash transfers for women in India aim to improve household welfare. Over 15 states have implemented these schemes, costing ₹2.68 lakh crores and benefiting nearly 120 million women. Monthly payments between ₹1,000 and ₹2,500 support financial independence and empower families, fostering economic growth and stability.
View File→
Business1 hour ago
Glenmark Pharma Settles $15.28M Antitrust Case with Humana
Glenmark Pharma's US subsidiary settles a $15.28 million antitrust case with Humana over generic drug pricing. This settlement addresses allegations of market allocation and anti-competitive practices in the pharmaceutical industry. The agreement aims to resolve concerns regarding fair pricing and competition in the generic drug market.
View File→